Avelumab Bavencio®
Avelumab is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The SHIKARI® Avelumab portfolio supports quantitative analysis of free avelumab and qualitative detection of specific anti-avelumab antibodies in human serum or plasma.
Why Avelumab is relevant to biological-drug monitoring research
Avelumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Avelumab is a human IgG1 monoclonal antibody that binds PD-L1 and blocks its interactions with PD-1 and B7.1. Source ↗
Approved Indications
EMA-authorised uses include metastatic Merkel cell carcinoma, advanced renal cell carcinoma in combination with axitinib, and first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma after platinum-based chemotherapy. EMA source ↗
Observed Study Trough Concentrations
In an EMA-assessed study using avelumab 10 mg/kg every two weeks, observed serum trough concentrations increased over time:
Two verified Avelumab research assays
Ligand-binding, sandwich-principle ELISA for the quantitative analysis of free avelumab capable of binding PD-L1 in human serum or plasma.
Sandwich-principle ELISA for qualitative detection of binding antibodies to avelumab in human serum or plasma, reported as positive or negative according to the assay-specific cut-off criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Mode | Analyte | Sample | Volume | Run Time | Analytical Output / LOD | Tests | Shelf Life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-AVE | AVE-FD-BAV | Quantitative | Free avelumab | Human serum / plasma | 10 µL | 70 min | LOD 30 ng/mL · LOQ 100 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAV | AVE-QLS-BAV | Qualitative | Antibodies to avelumab | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Q-AVE has a lowest detection limit (LOD) of 30 ng/mL and functional sensitivity (LOQ) of 100 ng/mL. Follow the link on each assay card for the current official product record on matriksbiotek.com.
Which assay fits your research question?
Choose the quantitative free-drug assay or qualitative anti-drug-antibody assay according to the analytical output required by the study.
Avelumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Avelumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.